Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor
Gastric Cancer - Colorectal Cancer - Chemotherapy
Conditions: official terms
Colorectal Neoplasms - Stomach Neoplasms
Conditions: Keywords
gastric cancer, colorectal cancer, chemotherapy, eicosapentaenoic acid, enteral nutrition
Study Type
Study Phase
Phase 3
Study Design
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment
Name: Nutriall Type: Drug
Name: LDEPA Type: Drug
Name: Placebo Type: Drug
Name: HDEPA Type: Drug
Name: Chemotherapy Type: Drug
Overall Status
Malnutrition is frequently seen in patients on chemotherapy suffering from gastric/colorectal cancer and may worsen the outcome. EPA, a sort of ω-3 PUFA, can modulate immune system. EPA also antagonizes metabolic and inflammatory changes induced by the tumor. This study is to test whether EPA, in combination with enteral nutrition, can improve nutritional/immunologic status, quality of life, and reduce chemotherapy related side effects of these patients.
Detailed Description
Chemotherapy is indispensible for patients suffering from advanced gastric or colorectal cancer, and also the main therapy for those with end-stage tumor. However, incidence of malnutrition during chemotherapy was reported as high as 60%. The mechanisms include anatomy modification of digestive tract, side effects of chemotherapy such as anorexia, nausea, vomiting, and inflammatory factors generated or induced by the tumor. Malnutrition may lead to discontinuation of the therapy, compromise of the anti-cancer effect, increase of toxicity and mortality. 20%-40% of patients with end-stage tumor ultimately died from malnutrition.

EPA (Eicosapentaenoic acid, molecular formula C20H30O2) belongs to ω-3 polyunsaturated fatty acid (ω-3 PUFA). EPA is one of the main constituent of fish oil. EPA decreases LPS-stimulated macrophage production of TNF-α, IL-1β, IL-6, and human B lymphocytes production of IL-10, TNF-α, IFN-γ. EPA can suppress cancer induced lipolysis, and enhanced the inhibitory effect of 5-Fu over cancer cell proliferation. However, cancer patients are always lack of EPA.

Nutriall is a sort of non-elemental diet. The kind of powder is produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE. For this enteral nutrition preparation, there have been evidences of protective effects on nutritional status during chemotherapy on lung cancer. However, this kind of preparation does not contain EPA.

Up to date, there has been no RCT which testified whether therapeutic dosage of EPA plus enteral nutrition has combined effects on patients receiving chemotherapy. The investigators choose nutriall as basic nutritional support agent during chemotherapy, and give patients different dosage of EPA. Nutritional and immunologic status, quality of life and side effects of chemotherapy are recorded to evaluate whether EPA can improve outcome of these patients. Through this study the investigators may also optimize the dose of EPA for patients receiving chemotherapy on gastric/colorectal cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: Inclusion Criteria:

- The cases have undergone radical excision on gastric cancer or colorectal cancer.

- Without contraindication for chemotherapy.

- Eligible for postoperative adjuvant XELOX chemotherapy.

- Capable of taking in food or drug orally.

- Without severe absorption dysfunction

- Able and willing to give written, informed consent

Exclusion Criteria:

- Comorbidities: diseases of hematology or immunology system; hepatic or renal dysfunction; metabolic diseases.

- BMI>35kg/m2

- Life expectancy≤3mo

- The chemotherapy treatment is palliative.

- The patient has received radiotherapy or neoadjuvant chemotherapy prior to the operation.
First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Status: Recruiting
Contact: Han-ping Shi, MD, PhD - 86-0-13802741263 - shihp38@hotmail.com
Start Date
December 2009
Completion Date
January 2012
Sun Yat-sen University
Sun Yat-sen University
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page